Retinopathy of prematurity in Saudi Arabia: Exploring maternal risk factors

Nooran Badeeb1*, Lina Raffa2, Huda AhmedHussain3, Dania Bamefleh2, Enas Mgharbil2, Sarah Alessa2, Aliaa Alamri4, Mohamed Albahiti2

Abstract:
PURPOSE: Retinopathy of prematurity (ROP) is a preventable blinding disorder affecting preterm infants. To date, maternal risk factors have not been studied in Saudi Arabia. This study aims to identify possible maternal risk factors for any stage and type 1 ROP.

MATERIALS AND METHODS: A total of 295 preterm infants screened for ROP between November 2013 and December 2018 at a Saudi Arabian tertiary-care hospital were included. We included infants with a gestational age ≤ 32 weeks and/or birth weight (BW) ≤ 1500 g. We analyzed 28 maternal and neonatal risk factors.

RESULTS: The incidence of ROP at any stage and Type 1 were 31.9% and 7%, respectively. In the univariate analysis, the only maternal factor associated with any stage of ROP was spontaneous vaginal delivery ($P = 0.049$), but no maternal factor was an independent risk factor for type 1 ROP. Multivariate logistic regression analysis identified lower BW, lower gestational age and longer neonatal intensive care unit stay as independent risk factors for the development of ROP at any stage ($P < 0.05$). For Type 1 ROP, lower BW, and intraventricular hemorrhage were significant independent risk factors ($P < 0.05$).

CONCLUSION: The only maternal risk factor related to ROP was spontaneous vaginal delivery, which increased the risk of any stage of ROP. The single most predictive risk factor for any stage of ROP and Type 1 ROP was low BW. These findings emphasize the role of the obstetrician in promoting health care and modifying maternal risk factors to prevent preterm births related to a low BW.

Keywords: Birth weight, maternal, neonatal, retinopathy of prematurity, risk factor

Introduction

Retinopathy of prematurity (ROP) is a disease in premature infants affecting the development of retinal blood vessels and can lead to blindness early in life.[1] ROP has been described as the second most frequent morbidity in a Saudi Arabian neonatal intensive care unit (NICU), only exceeded by respiratory distress syndrome (RDS).[2] The incidence of ROP in Saudi Arabia has been reported to range from 23% to 56%.[3-6] To better manage ROP, we need to study the disease as an event affected by various factors occurring before pregnancy, during pregnancy, and after birth.[7-9] Many studies have identified neonatal risk factors including low gestational age (GA), low birth weight (BW), prolonged oxygen exposure, sepsis, interventricular hemorrhage, and blood transfusions are associated with ROP.[10-12] However, the relationship of other, especially maternal, risk factors has not been extensively examined.[13] No Saudi Arabian studies have evaluated maternal risk factors.[14-16]

How to cite this article: Badeeb N, Raffa L, AhmedHussain H, Bamefleh D, Mgharbil E, Alessa S, et al. Retinopathy of prematurity in Saudi Arabia: Exploring maternal risk factors. Taiwan J Ophthalmol 2021;11:359-66.
Studies have revealed an association of ROP with maternal age, smoking, mode of delivery, and diabetes. Preeclampsia plays a controversial role in ROP; while some studies reported an inverse relationship with ROP, others observed an increased risk of ROP. Specifically, maternal conditions associated with defects in placental circulation causing fetal hypoxia have raised interest. Results of a large study showed higher ROP incidences among infants whose mothers had the following complications during pregnancy: Heavy cigarette smoking, second or third trimester bleeding, severe diabetes or anemia, moderate-to-severe preeclampsia and ruptured fetal membranes with or without infection.

In this report, we studied a series of suspected maternal and neonatal risk factors for ROP to identify independent risk factors linked to the development of any stage or Type 1 ROP that require treatment. To the best of our knowledge, this is the first study to explore maternal risk factors in a Saudi population of preterm infants.

Materials and Methods

Research subjects
This retrospective cohort study was conducted at the NICU of a Saudi tertiary university hospital. Data were collected from medical records of patients admitted to the NICU between November 2013 and December 2018. We included all infants with a GA ≤32 weeks and/or BW ≤1500 g who were screened for ROP. Eligible infants who did not complete all screening sessions and/or did not have a recorded final ROP examination were excluded. The study was approved by the Institute’s Biomedical Ethics Research Committee (Reference No 156-15). Informed consent from the guardians was waived due to the retrospective nature of the study. The study has been conducted in accordance with the World Medical Associations’ Declaration of Helsinki.

The data collection included
Demographics
GA, BW, plurality (singleton or multiple), sex, and nationality.

Antenatal maternal risk factors
1. Hypertensive diseases of pregnancy: Chronic hypertension, preeclampsia, and eclampsia
2. Diabetes: Chronic and gestational diabetes
3. Pregnancy-related factors: Preterm premature rupture of membranes (PPROM), antenatal steroids (ANS), mode of delivery (Cesarean section [CS], spontaneous vaginal delivery [SVD]).

Neonatal risk factors
a. Birth data and course of admission: Apgar score at 1 and 5 min, resuscitation at birth, poor weight gain at 6 weeks and length of stay in the NICU
b. Neonatal comorbidities and interventions: Anemia, RDS, bronchopulmonary dysplasia (BPD), patent ductus arteriosus, intraventricular hemorrhage (IVH), hyperglycemia, oxygen therapy, surfactant therapy, blood transfusion, and insulin therapy.

Retinopathy of prematurity screening criteria
Screening criteria were based on the (2013) American Academy of Pediatrics policy. The first examination was performed at 4 weeks postdelivery or at a corrected GA of 31 weeks, whichever was later. The infants were followed up weekly or biweekly until full vascularization of zone 3 or ROP regression was confirmed. Patients needed treatment if they met the early treatment for ROP (ETROP) definition of type 1 ROP. Treatment with diode laser or anti-vascular endothelial growth factor (anti-VEGF; bevacizumab 0.675 mg/0.03 mL) followed the guidelines of the ETROP and bevacizumab eliminates the angiogenic threat of ROP (BEAT-ROP) studies. All findings and interventions were documented for each eye following the standardized documentation of the revised International Classification of ROP, including the zone (1–3), the stage (1–5), presence or absence and extent of the disease in clock hours.

The examination was performed by a pediatric ophthalmologist or a retina specialist experienced in ROP screening. Dilatation was initiated 1 h before the examination with cyclopentolate 0.25% and phenylephrine 2.5%, instilled three times every 10 min. A topical anesthetic was applied and a sterile pediatric speculum was used to open the eye. An indirect ophthalmoscope and a 28 diopter (D) lens were used with a sterile scleral depressor to examine the periphery of the fundus until the ora serrata was seen, the anterior border of the retinal vascularization was identified, or retinopathy was confirmed.

Statistical analysis
Data analysis was performed using the IBM Statistical Package for the Social Sciences (SPSS) Version 26.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were checked for normality using the Shapiro–Wilk test. Results were expressed as mean ± standard deviation for normally distributed data, median (interquartile range) for non normally distributed data and frequencies (proportions) for categorical variables. Student’s t-test was used to compare the means of continuous variables among those who developed ROP and those who did not.

Multivariate logistic regression analysis was used to identify predictors of ROP. Initially, a correlation matrix was created to check for high collinearity in any independent variables using Pearson’s or Spearman’s correlation tests according to the variable type and distribution. Univariate logistic regression was used
to examine the association of each potential predictor with the outcome variable (any stage ROP). Neonatal and maternal independent variables that were highly correlated were included in a multivariate logistic regression analysis (backward selection). The same process was performed when assessing possible related risk factors for the variable “type 1 ROP.” The final model included the significant neonatal and maternal predictors in addition to the well-known predictors of ROP (BW and GA). A subanalysis was performed to identify any difference between risk factors of infants born vaginally and those born by CS. The model fit was tested using Hosmer–Lemeshow goodness of fit statistic. Odds ratio (ORs) and 95% confidence intervals (CIs) for each predictor were reported. A \( P < 0.05 \) was considered statistically significant.

**Results**

In our study, 295 infants were screened, of which 94 (31.9%) had ROP of any stage in at least one eye during at least one examination and 21 (7%) was of type 1 ROP. Table 1 compares the incidence of ROP in our study with those in other studies conducted in different regions of Saudi Arabia. The majority of patients in our study had stage 1 ROP (66%), whereas 23%, 10% and 1% had stage 2, 3, and 4, respectively. Of the ROP-positive patients, only 21 (22%) required treatment in both or either eyes. The most frequent treatment was by laser in 14 patients (67%), both laser and anti-VEGF treatment with bevacizumab were needed in 4 patients (19%), bevacizumab alone was needed in 2 infants (10%) and surgical intervention in 1 (5%). The median time from birth to the initial detection of ROP was 40 days (range 24–177 days) and time to treatment was 72 days (range 39–179 days). After treatment, no recurrence was observed.

**Demographics**

Of the 295 infants enrolled in the study, 195 (66%) were from multiple birth pregnancy. Our data included 148 (51%) Saudi patients and almost equal numbers of males and females. The mean GA of the overall study group was 28.0 ± 2.4 weeks, and the mean BW was 1086.8 ± 266.6 g. Table 2 presents the characteristics among the three groups: No ROP, nontreated ROP and treated ROP group. None of the treated infants had a GA > 30 weeks (median, 28 weeks; range, 23–30 weeks) or a BW >1000 g (mean, 767.8 g; range, 527–1000 g).

**Maternal risk factors**

Only one maternal risk factor, i.e., SVD, increased the risk of any stage ROP in the univariate analysis (OR = 0.598, 95% CI 0.358–0.998, \( P = 0.049 \)). No other maternal risk factors were identified [Table 3]. With regards to indicators of hypoxia such as Apgar scores at 5 min, the need for oxygenation and resuscitation at birth, both SVD and CS groups had similar outcomes. In addition, vaginally delivered neonates did not have more comorbidities such as RDS, sepsis, and/or IVH. However, vaginally delivered neonates were found to have statistically significant lower GA (mean 28.2 ± 2.2) when compared to our CS (mean 29.2 ± 2.5) \( (P = 0.001) \).

**Neonatal risk factors**

The following factors were considered independent predictors for any stage ROP in the multivariate analysis: Lower BW, lower GA, and longer stay in the NICU [all \( P < 0.05 \); Table 4]. In the multivariate analysis of type 1, ROP BW and IVH were identified as significant independent risk factors [all \( P < 0.05 \); Table 5].

BW was the best predictor for both any stage ROP and type 1 ROP [Tables 4 and 5]. In the group of extremely preterm infants (GA < 28 weeks), there was a 7.0-fold increase in the risk of any stage ROP with each decrease in GA by 1 week (OR = 7.040, 95% CI 3.933–12.601, \( P < 0.001 \)). In the same group, the risk of treatment was increased by 3.2-fold with each decrease in GA by 1 week (OR = 3.203, 95% CI 1.117–9.186, \( P = 0.026 \)). In that group, the ROP incidence was 50%, and 71.4% of the affected infants needed ROP treatment.

**Discussion**

This study aimed to expand our knowledge on the risk factors for developing ROP in Saudi Arabia. In agreement with other studies,

**Table 1: Incidence of retinopathy of prematurity in the present study compared to those in other national studies**

| Authors            | Years | City        | GA (weeks) or BW (g) | Number of patients | ROP (%) |
|--------------------|-------|-------------|----------------------|--------------------|---------|
| Al-Amro et al[2]   | 2002  | Riyadh      | GA ≤34 or BW ≤2000   | 195                | 37.4    |
| Binkhathian et al.[4] | 2007  | Riyadh      | GA ≤36 or BW ≤2000   | 174                | 56.0    |
| Amer et al.[3]     | 2012  | Khamis Mushait | GA ≤32 or BW ≤1500   | 386                | 23.3    |
| Waheeb and Alshehri[5] | 2016  | Jeddah      | GA <32 or BW <1500   | 92                 | 33.7    |
| Al-Qahtani et al.[6] | 2019  | Riyadh      | GA <32 or BW <1501   | 581                | 38.6    |
| Present study      | 2020  | Jeddah      | GA ≤32 and/or BW ≤2000 | 295               | 31.9    |

ROP: Retinopathy of prematurity, GA: Gestational age, BW: Birth weight
Table 2: Characteristic of patients in the no retinopathy of prematurity and the retinopathy of prematurity groups

|                          | No ROP group (n=201) | ROP group (n=94) | P       |
|--------------------------|----------------------|-----------------|---------|
|                          | n=73                 | n=21            |         |
| Birth weight (g)         | 1158.8±246.4         | 980.6±244.0     | <0.001* |
| Gestational age (weeks)  | 29.6±2.3             | 27.6±1.7        | <0.001* |
| Length of stay in the NICU (days) | 52.0±33.7 | 74.3±37.0 | <0.001* |
| Weight gain at 6 weeks (g) | 523.6±218.3 | 429.0±193.6 | 0.002* |
| Apgar score at 1 min     | 5.5±2.2              | 5.1±2.2         | 0.076   |
| Apgar score at 5 min     | 7.8±1.5              | 7.5±1.7         | 0.153   |

ROP: Retinopathy of prematurity, NICU: Neonatal intensive care units

Table 3: Univariate and multivariate logistic regression analyses of maternal risk factor for any stage retinopathy of prematurity and type 1 retinopathy of prematurity

|                          | OR | 95% CI | P     | OR | 95% CI | P     |
|--------------------------|----|--------|-------|----|--------|-------|
| Any stage ROP            |    |        |       |    |        |       |
| Chronic hypertension    | 0.144 | 0.019 | 1.109 | 0.063 |          |        |
| Preeclampsia             | 0.765 | 0.416 | 1.405 | 0.388 |          |        |
| Eclampsia                | 0.409 | 0.115 | 1.448 | 0.166 |          |        |
| Gestational diabetes     | 1.073 | 0.356 | 3.232 | 0.900 |          |        |
| Chronic diabetes         | 0.674 | 0.622 | 0.730 | 0.999 |          |        |
| PPROM                    | 0.769 | 0.428 | 1.383 | 0.380 |          |        |
| Antenatal steroids       | 1.402 | 0.852 | 2.291 | 0.178 |          |        |
| Delivery mode (SVD)      | 0.598 | 0.358 | 0.998 | 0.049* | 0.520 | 0.188 | 1.442 | 0.209 |

Type 1 ROP

|                          | OR | 95% CI | P     | OR | 95% CI | P     |
|--------------------------|----|--------|-------|----|--------|-------|
| Chronic hypertension    | 0.774 | 0.694 | 0.864 | 1.000 |          |        |
| Preeclampsia             | 1.054 | 0.305 | 3.644 | 0.934 |          |        |
| Eclampsia                | 7.579 | 0.652 | 88.101 | 0.106 |          |        |
| Gestational diabetes     | 2.456 | 0.382 | 15.772 | 0.344 |          |        |
| Chronic diabetes         | -   | -     | -     | -   |          |        |
| PPROM                    | 0.193 | 0.024 | 1.559 | 0.123 |          |        |
| Antenatal steroids       | 0.619 | 0.232 | 1.648 | 0.337f |          |        |
| Delivery mode (SVD)      | 0.684 | 0.257 | 1.820 | 0.447 |          |        |

ROP: Retinopathy of prematurity, OR: Odds ratio, CI: Confidence intervals, PPROM: Preterm premature rupture of membranes, SVD: Spontaneous vaginal delivery

with previous studies in the literature, low BW remains the single most predictive risk factor for both, any stage ROP and type 1 ROP. In our study, intrauterine growth was more important than maturity, as BW but not GA was the best predictor for any stage ROP and type 1 ROP. This was not the case in the study in China by Yau et al. where GA but not BW was the best predictor for any stage ROP. A study in Turkey by Bas et al. showed that both GA and BW were independent risk factors for severe ROP. Another study in India by Rao et al. showed increased risk of ROP in older infants with GA of 31–32 weeks, as their infants of < 28 weeks had lower survival rates. These studies highlight the difference in characteristics, quality of care, and risk factors for each population.

Studies regarding the incidence of ROP in the population of Saudi Arabia have reported contradictory findings [Table 1]. In our study, 31.9% of premature infants developed ROP, which is similar to what has been reported in the same region by Waheeb et al. These rates are lower than that reported in the Central region of Saudi Arabia by Al-Qahtani et al., Al-Amro et al., and Binkhathlan et al. and higher than that reported in the South-West region by Amer et al. These discrepancies might be attributed to the fact that no national guidelines for screening of ROP has been applied in Saudi Arabia despite a standardized protocol for ROP screening has been suggested in 2018.

BW and GA are the most predictive risk factors for ROP. In our study, intrauterine growth was more important than maturity, as BW but not GA was the best predictor for any stage ROP and type 1 ROP. This was not the case in the study in China by Yau et al. where GA but not BW was the best predictor for any stage ROP. A study in Turkey by Bas et al. showed that both GA and BW were independent risk factors for severe ROP. Another study in India by Rao et al. showed increased risk of ROP in older infants with GA of 31–32 weeks, as their infants of < 28 weeks had lower survival rates. These studies highlight the difference in characteristics, quality of care, and risk factors for each population.

The association between mode of delivery and ROP is controversial. Manzoni et al. and Sasaki et al. reported a positive relationship between threshold ROP and delivery by SVD. Manzoni et al. attributed this to the risk of hypoxia during SVD, which could aggravate the progression of ROP, and suggested it as one of the risk factors to consider for closely following up an ROP
Table 5: Univariate and multivariate logistic regression analyses for neonatal risk factors in type 1 retinopathy of prematurity group

|                | Univariate |                      |            |          |          |               |          |          |          |          |          |          |          |          |          |          |          |
|----------------|------------|----------------------|-----------|----------|----------|--------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|                | OR         | 95% CI               | P         | OR       | 95% CI   | P            |          |          |          |          |          |          |          |          |          |          |          |
|                | Lower      | Upper                |           | Lower    | Upper    |              |          |          |          |          |          |          |          |          |          |          |          |
| Sex            | 1.379      | 0.668                | 0.407     | 1.96     | 0.110    |               |          |          |          |          |          |          |          |          |          |          |          |
| Nationality    | 1.415      | 0.846                | 2.318     | 0.167    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Multiple births| 1.082      | 0.646                | 1.811     | 0.764    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Gestational age| 0.996      | 0.864                | 2.238     | 0.519    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Birth weight   | 0.736      | 0.384                | 1.448     | 0.008    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Apgar score at 1 min | 0.998 | 0.582                | 0.999    | 0.110    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Apgar score at 5 min | 0.918 | 0.592                | 1.421     | 0.003    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Resuscitation at birth | 0.998 | 0.582                | 1.421     | 0.008    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Weight gain at 6 weeks | 0.998 | 0.996                | 0.999    | 0.008    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Length of stay in the NICU | 0.996 | 0.996                | 0.999    | 0.008    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Anemia         | 2.250      | 1.324                | 3.824     | 0.003    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Oxygen therapy | 1.917      | 0.961                | 2.206     | 0.011    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| RDS            | 1.376      | 0.706                | 2.700     | 0.394    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| BPD            | 2.615      | 0.854                | 8.009     | 0.002    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| PDA            | 1.422      | 0.854                | 2.368     | 0.176    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| IVH            | 1.634      | 0.961                | 2.779     | 0.070    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Hyperglycemia  | 1.676      | 0.909                | 2.700     | 0.098    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Surfactant     | 2.400      | 1.346                | 4.280     | 0.003    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Blood transfusion | 0.822 | 0.496                | 1.364     | 0.044    |          |               |          |          |          |          |          |          |          |          |          |          |          |
| Insulin        | 2.540      | 0.996                | 6.478     | 0.051    |          |               |          |          |          |          |          |          |          |          |          |          |          |

NICU: Neonatal intensive care units, OR: Odds ratio, CI: Confidence interval, RDS: Respiratory distress syndrome, BPD: Bronchopulmonary dysplasia, IVH: Intraventricular hemorrhage

On the other hand, Holmström et al. determined no significant relationship between ROP and SVD. Our study has identified that infants born by SVD were more likely to develop any stage ROP in the univariate analysis. Based on our results, oxygenation, Apgar scores, resuscitation at birth, and neonatal morbidities were
Similar between infants born using different modes of delivery. However, lower GA was found in the neonates born vaginally compared to those born by CS and since lower GA is a risk factor for ROP development, this might explain why SVD was found as a risk factor in our cohort.\cite{10,11} In our opinion, this established relationship between SVD and ROP could be an association rather than causation. Although CS could increase the risk of maternal comorbidities, it is thought to reduce the incidence of neonatal comorbidities especially in infants born from week 23 + 0 to week 27 + 6 of GA.\cite{16,17}

Various reports have evaluated maternal risk factors and the development of ROP.\cite{7,11,20,27-30} It is speculated that the pathogenesis of ROP starts in utero and is multifactorial, but based on the current literature, antenatal risk factors still play an undetermined role.\cite{7,9}

In our study, neither preeclampsia nor eclampsia had an increased correlation with any stage ROP or Type 1 ROP. A recent meta-analysis including 13 cohort studies related to hypertensive diseases of pregnancy found no clear relationship between ROP and hypertensive pregnancy diseases including; preeclampsia, eclampsia, and gestational hypertension; furthermore, most of these studies were found to be insufficient and subject to bias; therefore, the results remain controversial.\cite{13} There is no concrete evidence of how hypertensive diseases of pregnancy affect ROP; however, studies that suggested that an increase of soluble fms-like tyrosine kinase-1 (sFlt-1) in the plasma of preeclamptic mothers could provide protective effect, since it is a VEGF and placental growth factor agonist which can cross the placenta.\cite{19,20,30,31} Conversely, studies that suggested an increased risk of ROP with preeclampsia observed dysregulation of angiogenic factors associated with placental defective circulation and oxidative stress. Moreover, they reported that placental ischemia might cause retinal hypoxia and elevation of VEGF in preterm infants, thus, causing ROP.\cite{20}

In our study, essential hypertension was observed in a few mothers with preterm births due to the nature of this chronic disease, which is usually related to advanced age.\cite{20} Hypertension causes more pregnancy-related complications including an increased risk of preterm delivery, BW below the 10th percentile for the GA, intrauterine growth restriction, preeclampsia and a higher risk of CS delivery.\cite{30} Although Holmström et al. reported a trend toward more ROP cases in mothers with preexisting chronic hypertension, we did not find that chronic hypertension was correlated with ROP.\cite{27} This could be because in our study all hypertensive patients were delivered by CS, and CS was protective.

Other maternal risk factors like diabetes were suggested to have a role in ROP. Purohit et al. proposed that babies of mothers with diabetes have higher levels of hyperglycemia, which leads to vasodilation, further stimulating neovascularization.\cite{27} However, a study by Bental et al. showed no relation between gestational diabetes and severe ROP stages 3 and 4.\cite{29} Holmström et al. reported no increase in any stage ROP in mothers with chronic diabetes.\cite{27} Similarly, our reports show no increased risk of any stage ROP or Type 1 ROP that needs treatment in mothers with diabetes.\cite{27}

Conflicting data have been published about PPROM as a risk factor. A study by Lee et al. and Lynch et al. have shown that PPROM might have a protective effect, by allowing the time for administration of steroids and antibiotics before delivery.\cite{7,24} On the other hand, a study by Ozdemir et al. found that mothers with PPROM of > 18 h had an increased risk of infants with severe ROP, this was attributed to the infection and inflammation experienced during this phase.\cite{30} Meanwhile, Holmström et al. reported insignificant relationship between PPROM and ROP.\cite{27} Similarly, PPROM was neither protective nor increased the risk of ROP in our study.

Among mothers, who went into preterm delivery almost half of them, 47.5% received ANS. This point of view was supported by Bas et al. who reported an increase in ROP in a group of mothers that did not receive two doses of ANS.\cite{10} It is suggested that ANS could improve systemic circulation and angiogenesis, playing a pivotal role in the maturation of the cerebral vasculature.\cite{30} Sasaki et al. reported that ANS decreased the risk of mortality in extremely preterm infants as well as the risk of developing any stage ROP.\cite{28} However, Eriksson et al. reported the increased risk of ROP in infants receiving ANS.\cite{37} Our study findings were similar to those by Rao et al. and Yau et al. where no protective or predisposing ANS effect was observed.\cite{11,12}

There are some limitations to the present study. This study was retrospective in nature. ROP screening was done by multiple ophthalmologists, causing possible inter-observer variability. The small sample size was contributed by the fact that 80% of preterm deliveries are neonates >32 weeks, whereas according to the ROP screening criteria, we only examined infants with a GA ≤32 weeks. Finally, we included mothers with multiple births, possibly affecting the analysis of maternal risk factors. However, this is the first study to investigate and identify maternal risk factors in Saudi Arabia. Thus, the present study could serve as a benchmark for further local studies.

**Conclusion**

Lower GA, lower BW, and longer NICU stays were important predictors of any stage ROP and type 1 ROP.
Of those, lower BW was the only shared independent risk factor. This emphasizes the role of the obstetrician in antenatal care to promote better health and modify maternal risk factors that might lead to earlier deliveries with lower BW values. Moreover, there were no maternal associations, except for deliveries by SVD, which was a risk factor for any stage ROP. Additional projects are needed to monitor neonatal standards of care in local institutes in Saudi Arabia to improve ROP outcomes, and future collaborative multicenter studies are needed to enrich our understanding of the major risk factors that play a role in the pathophysiology of the disease in our region and allow us to tailor ROP managements.

Acknowledgment

The authors would like to thank Dr. Hanan Al Kadi, Associate Professor, Department of Physiology, King Abdulaziz University, Faculty of medicine for doing the statistical analysis. And for the work on data collection, we would like to thank Abdulaziz Aldahlawi, Angie Felimban, Badr Aldahlawi, Emad Alfaiel, Lama Mahboub.

We would like to thank Editage (www.editage.com) for English language editing.

Financial support and sponsorship

Nil.

Conflicts of interest

The authors declare that there are no conflicts of interests of this paper.

References

1. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and early course of retinopathy of prematurity. The cryotherapy for retinopathy of prematurity cooperative Group. Ophthalmology 1991;98:1628-40.

2. Al-Amro SA, Al-Kharfi TM, Thabit AA, Al-Mofada SM. Retinopathy of prematurity at a University Hospital in Riyadh, Saudi Arabia. Saudi Med J 2003;24:720-4.

3. Amer M, Jafari WH, Nizami AM, Shomrani AI, Al-Dabaan AA, Rashid K. Retinopathy of prematurity: Are we missing any infant with retinopathy of prematurity? Br J Ophthalmol 2012;96:1052-5.

4. Binkhathlan AA, Almahmoud LA, Saleh MJ, Srungeri S. Retinopathy of prematurity in Saudi Arabia: Incidence, risk factors, and the applicability of current screening criteria. Br J Ophthalmol 2008;92:167-9.

5. Waheed S, Alshehri K. Incidence of retinopathy of prematurity at two tertiary centers in Jeddah, Saudi Arabia. Saudi J Ophthalmol 2016;30:109-12.

6. Al-Qahtani B, Al-Otaibi M, AlabduLajabbar K, Selayem NB, Alshehri W, Omair A, et al. Retinopathy of prematurity incidence and risk factors in a tertiary hospital in Riyadh, Saudi Arabia. Middle East Afr J Ophthalmol 2019;26:235-9.

7. Lee JW, McElrath T, Chen M, Wallace DK, Allred EN, Leviton A, et al. Pregnancy disorders appear to modify the risk for retinopathy of prematurity associated with neonatal hyperoxemia and bacteremia. J Matern Fetal Neonatal Med 2013;26:811-8.

8. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res 2004;14 Suppl A: S140-4.

9. Kindinger LM, David AL. The role of the obstetrician in the prevention of retinopathy of prematurity. Semin Perinatol 2019;43:323-32.

10. Bas AY, Demirel N, Koc E, Ulubas Isik D, Hirfanoglu IM, Tunc T, et al. Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): A prospective, multicentre study in 69 neonatal intensive care units. Br J Ophthalmol 2018;102:1711-6.

11. Rao KA, Purkayastha J, Hazarika M, Chaitra R, Mithun Adith K. Analysis of prenatal and postnatal risk factors of retinopathy of prematurity in a tertiary care hospital in South India. Indian J Ophthalmol 2013;61:640-4.

12. Yau GS, Lee JW, Tam VT, Liu CC, Wong YJ. Risk factors for retinopathy of prematurity in extremely preterm Chinese infants. Medicine (Baltimore) 2014;93:e314.

13. Zhu T, Zhang L, Zhao F, Qu Y, Mu D. Association of maternal hypertensive disorders with retinopathy of prematurity: A systematic review and meta-analysis. PLoS One 2017;12:e0175374.

14. Uchida A, Miwa M, Shinoda H, Kato T, Nagai N, Mochimaru H, et al. Association of maternal age to development and progression of retinopathy of prematurity in infants of gestational age under 33 weeks. J Ophthalmol 2014;2014:187929.

15. Johnson L, Schaffer D, Blesa M, Boggs T. 981 factors predisposing to RLF-complications of pregnancy. Pediatr Res 1978;12(527).

16. Holzer I, Lehner R, Ristl R, Husslein PW, Berger A, Furr A. Effect of delivery mode on neonatal outcome among preterm infants: An observational study. Wien Klin Wochenschr 2017;129:612-7.

17. Manzoni P, Farina D, Maestri A, Giovannozzi C, Leonessa ML, Arisio R, et al. Mode of delivery and threshold retinopathy of prematurity in pre-term ELBW neonates. Acta Paediatr 2007;96:221-6.

18. Purohit DM, Ellison RC, Zierler S, Miettinen OS, Nadas AS. Risk factors for retrolental fibroplasia: Experience with 3,025 premature infants. National Collaborative Study on Patent Ductus Arteriosus in Premature Infants. Pediatrics 1985;76:339-44.

19. Fortes Filho JB, Costa MC, Eckert GU, Santos PG, Silveira RC, Prociacojy RS. Maternal preeclampsia protects preterm infants against severe retinopathy of prematurity. J Pediatr 2011;158:372-6.

20. Ozkan H, Cetinkaya M, Koskak N, Ozmen A, Yildiz M. Maternal preeclampsia is associated with an increased risk of retinopathy of prematurity. J Perinat Med 2011;39:523-7.

21. Fierson WM; American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013;131:189-95.

22. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94.

23. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity. N Engl J Med 2011;364:603-15.

24. International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005;123:991-9.

25. Al Amro SA, Al Aql F, Al Hajar S, Al Dhibi H, Al Nemri A, Mousa A, et al. Practical guidelines for screening and treatment of retinopathy of prematurity in Saudi Arabia. Saudi J Ophthalmol 2018;32:222-6.

26. Sasaki Y, Ikeda T, Nishimura K, Katsuragi S, Sengoku K, Kusuda S, et al. Association of antenatal corticosteroids and the mode of delivery with the mortality and morbidity of infants weighing less than 1,500 g at Birth in Japan. Neonatology 2014;106:81-6.
27. Holmström G, Thomassen P, Broberger U. Maternal risk factors for retinopathy of prematurity—a population-based study. Acta Obstet Gynecol Scand 1996;75:628-35.
28. Lynch AM, Berning AA, Thevarajah TS, Wagner BD, Post MD, McCourt EA, et al. The role of the maternal and fetal inflammatory response in retinopathy of prematurity. Am J Reprod Immunol 2018;80:e12986.
29. Bental Y, Reichman B, Shiff Y, Weisbrod M, Boyko V, Lerner-Geva L, et al. Impact of maternal diabetes mellitus on mortality and morbidity of preterm infants (24-33 weeks' gestation). Pediatrics 2011;128:e848-55.
30. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007;197:28.e1-6.
31. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
32. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 2011;123:e18-209.
33. Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation 2014;129:1254-61.
34. Lynch AM, Wagner BD, Hodges JK, Thevarajah TS, McCourt EA, Cerda AM, et al. The relationship of the subtypes of preterm birth with retinopathy of prematurity. Am J Obstet Gynecol 2017;217:354.e1-0000000.
35. Ozdemir R, Sari FN, Tunay ZO, Erdeve O, Canpolat FE, Oguz SS, et al. The association between respiratory tract Ureaplasma Urealyticum colonization and severe retinopathy of prematurity in preterm infants ≤1250 g. Eye (Lond) 2012;26:992-6.
36. Vinukonda G, Dummla K, Malik S, Hu F, Thompson CI, Csizsar A, et al. Effect of prenatal glucocorticoids on cerebral vasculature of the developing brain. Stroke 2010;41:1766-73.
37. Eriksson L, Haglund B, Ewald U, Odlind V, Kieler H. Short and long-term effects of antenatal corticosteroids assessed in a cohort of 7,827 children born preterm. Acta Obstet Gynecol Scand 2009;88:933-8.